DMRA · ISSUER CIK 1800315
Damora Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 1 Damora Therapeutics, Inc. insiders reported $253K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Jarrett Jennifer (Director, President and CEO, Director), with $253K.
↗1 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$253KInsider buying
$0.00Insider selling
+$253KNet open-market
Sep 28, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 202607:00 | Sep 25, 2026 | DMRA | Director, President and CEO, Director | P · Buy | $20.23 | +12,500 | 512,500 | +3% | +$253K | -38.7% | +8.8% |